益肝降脂方对酒精性脂肪肝SD大鼠D-乳酸和二胺氧化酶的预防效应分析

Prevention effect analysis of the Yigan Jiangzhi prescription on D-lactic acid and diamine oxidase in SD rats with alcoholic fatty liver disease

关键词:  益肝降脂方  酒精性脂肪肝  肠道屏障  D-乳酸  二胺氧化酶

Key words:  Yigan Jiangzhi prescription  alcoholic fatty liver  intestinal barrier  D-lactic acid  diamine oxidase

摘要:

[目的] 观察益肝降脂方（YGJZF）不同阶段干预对酒精性脂肪肝（AFLD）SD大鼠D-乳酸（D-LA）、二胺氧化酶（DAO）的预防效应，分析益肝降脂方对肠黏膜屏障可能的机制。[方法] 将97只SD大鼠适应性喂养1周后，随机分为模型组22只、YGJZF组75只，按干预时段的不同YGJZF组分为第3周用药、第6周用药、第9周用药3组。模型组予高脂+乙醇灌胃进行酒精性脂肪肝造模，YGJZF组在模型组基础上用药干预。分别于实验不同时段处死大鼠，观察各组大鼠体质量、肝湿重、肝指数变化，血清D-LA、DAO的含量，同时检测大鼠血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、甘油三酯（TG）、总胆固醇（TC）含量。HE染色观察大鼠肝脏组织病理学和肠道组织病理形态变化。[结果]随着造模时间的延长，大鼠体质量及肝湿重均明显升高，与模型组相比，YGJZF组体质量增加更明显。与模型组相比，不同时段YGJZF组血清D-LA、DAO的含量均显着降低（P<0.05）。模型组大鼠ALT、AST、TG、TC水平明显升高，与不同时段YGJZF组比较，差异有统计学意义（P<0.05）；D-LA及DAO活力高低与肠道组织病理变化趋势呈正向相关，也与肝脏组织病理损伤有相关性。[结论] 1）益肝降脂方预防性给药能够保护肠黏膜屏障，其可能的机制与降低酒精性脂肪肝大鼠血清D-LA、DAO有关。2）益肝降脂方降低血清D-LA、DAO含量的同时减轻酒精性脂肪肝大鼠肝脏损伤。3）益肝降脂方不同阶段干预造模均对酒精性脂肪肝大鼠肠道屏障具有预防保护作用，而早期干预效果明显。

Abstract:

[Objective] To observe the impact of prevention effect in different stages of the Yigan Jiangzhi prescription(YGJZP) on D-lactic acid (D-LA) and diamine oxidase (DAO) of alcoholic fatty liver disease (AFLD) of SD rats and analyze the protective mechanism of YGJZP on the intestinal mucosal barrier. [Methods] The 97 SD rats were randomly divided into 22 rats in model group, 75 rats in YGJZF group. According to the different intervention time, YGJZF groups were divided into 3 groups, including the third week medication, the sixth week medication, the ninth week medication. Model group was given fat diet combined with alcohol feeding to produce the model of alcoholic fatty liver. Medicine group was given medicine intervention on the basis of the model group. Finally, rats were respectively sacrificed at different stages of the experiment, to observe the body weight, liver wet weight, liver index of rats, the contents of serum D-LA, DAO, and detect of the contents of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) as well as triglyceride cholesterol (T-CHO) simultaneously. HE staining was used to observe the changes of liver histopathology and the morphology of the intestinal tissue. [Results] With the modeling time prolongs, compared with model group, the body weight and liver wet weights of rats were increased significantly, and the body weight of YGJZF group increased significantly. Compared with the model group, the serum levels of D-LA and DAO in YGJZF group of different periods were significantly lower (P<0.05). The levels of ALT, AST, TG, TC in model group were significantly increased, compared with YGJZF group of different periods. The difference was statistically significant (P<0.05). The activity of D-LA and DAO were correlated with the pathological changes of intestinal tissue were positively correlated trends, and also related with liver histopathological damage. [Conclusion] 1) Preventive administration of YGJZP can protect against the intestinal mucosa, and its possible mechanism may associated with decreasing the serum levels of D-LA, DAO in rats with alcoholic fatty liver. 2) YGJZP can reduce contents of D-LA, DAO and decrease the alcoholic fatty liver damage. 3) YGJZF has played a role in the prevention and protection of intestinal mucosal barrier at different stages among the experimental intervention, especially at the early intervention is more effective.